NCT Number: NCT00199654
Positron Emission Tomography (PET) Interest in the Follow Up of Colorectal Cancer Stage II and III
The follow up of colorectal cancer after curative surgery has to find loco-regional relapses or synchronous metastases, and to detect adenomas and new cancer on the rest of the colon.
The increase of survival after relapse of the colorectal cancer depends on the possibility of curative action or after chemotherapy response.
This is a Phase III open-labeled, multicenter, multidisciplinary, randomised study, comparing 2 arms of 188 patients (i.e. 376 total patients).
Study Period (date of first inclusion/last inclusion): 3 years.
Follow Up: 3 years.
The primary objective is the evaluation of PET performance in the earlier relapse detection of the colorectal cancer relapse in comparison with conventional control (including carcinoembryonic [CEA] levels and other classic radiological exams).
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
Cancérologie et Hépato-Gastro-Entérologie, Bordeaux, France
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Signed and dated written informed consent
- Confirmed stage II or III (TNM)
- Patient with curative surgery for colorectal adenocarcinoma
- Total digestive endoscopy prior or post surgery.
- Age > 18 years old
- Normal liver ultrasound and chest X-ray or thoraco-abdomino pelvic computed tomography (CT) scan.
- In fertile women, efficient contraception or postmenopausal patient (amenorrhea for at least 1 year)
Exclusion criteria
- Serious concomitant pathology
- Uncontrolled diabetes with a classical treatment (glycaemia >1.4 g/l)
- Other malignant tumour within the last 5 years (except for curatively treated basocellular carcinoma of the skin or in situ cervical carcinoma).
- Uncontrolled infection
- Women who are pregnant or lactating
- Inability to understand informed consent
- Psychological or geographic impossibility to follow up for three years.
Treatment and study plan
Primary outcomes
-
Time to colorectal cancer relapse
Secondary outcomes
-
Evaluation of overall survival in the two groups
Time frame: after curative resection of colorectal cancer stage II or III
-
Evaluation of the rate of curative surgery
Time frame: after relapse
-
Comparison of the medical cost in the two detection strategies
Sponsors and collaborators
Lead sponsor
University Hospital, Limoges
Other
Registry information
Official study title
PET Interest in the Follow Up of Colorectal Cancer Stage II and III: Phase III Randomised Study
Important dates
- Study start
- 2004
- Primary completion
- 2012
- Study completion
- 2013
- First posted
- Sep 20, 2005
- Registry last updated
- Apr 9, 2013
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Telerehabilitation in Cancer Patients: Optimization of Prehabilitation and Rehabilitation Following Colorectal Resection
NCT06593678
Colonic Diseases, Colorectal Cancer
Zaragoza, Spain
View Trial DetailsCetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
NCT00265850
Colonic Diseases, Colonic Neoplasms
Mobile, Alabama, United States
View Trial DetailsPsychological Evaluation According Colonic Colonization by Escherichia Coli of Patients After Colorectal Surgery
NCT02970513
Bacterial Infections, Bacterial Infections and Mycoses
Clermont-Ferrand, France
View Trial DetailsTumor-Derived FGF19
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial Details